The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
DEA & DOJ Officially Submit Proposal for Cannabis Rescheduling, Setting Comment Period in Motion
The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
Could Rescheduling Finally Bring Institutional Investment in to Cannabis?
Next PostAkanda Implements 2nd Stock Split Amid Debt Woes, DanCann Pharma Earnings Fall Due to Strategy Change, & More From Celadon
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, they have researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Related Posts
Related Posts
Senate Committee Passes ‘Hemp Killing’ Legislation, But Gives Hemp Businesses 1 Year Delay
Efforts to close the so-called ‘hemp loophole’ in the US, which would have banned the sale of hemp-derived products containing...
US Cannabis Rescheduling Process Has Seen no Progress 6 Months After ‘Temporary’ Suspension
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement...
US House Votes to Allow VA Doctors to Recommend Medical Cannabis in Landmark Veterans Health Bill
The New Federal Government Drugs Commissioner Remains Vague on the Cannabis Issue
Delaware to Launch Recreational Cannabis Sales on 1 August
‘Seminal Moment’: Texas Hemp-Killing Bill Blocked as State Doubles Down on Medical Cannabis
CONNECT
Related Posts
Related Posts
Senate Committee Passes ‘Hemp Killing’ Legislation, But Gives Hemp Businesses 1 Year Delay
Efforts to close the so-called ‘hemp loophole’ in the US, which would have banned the sale of hemp-derived products containing...
US Cannabis Rescheduling Process Has Seen no Progress 6 Months After ‘Temporary’ Suspension
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement...
US House Votes to Allow VA Doctors to Recommend Medical Cannabis in Landmark Veterans Health Bill
Doctors at the US Department of Veterans Affairs (VA) may soon be allowed to recommend medical cannabis to patients, following...
The New Federal Government Drugs Commissioner Remains Vague on the Cannabis Issue
With the appointment of Prof. Dr. Hendrik Streeck as the new Federal Government Commissioner for Drugs, Burkhard Blienert had to...
Delaware to Launch Recreational Cannabis Sales on 1 August
Delaware will become the 22nd US state to launch a regulated adult-use cannabis market when retail sales begin on 1...
Recent Posts
Related Posts
US Cannabis Rescheduling Process Has Seen no Progress 6 Months After ‘Temporary’ Suspension
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement...
Cannabis Exodus from Public Markets Continues: Celadon Announces Plans to Leave AIM and IMC Fights to Remain on NASDAQ
The exodus of listed cannabis companies from the public markets, particularly in the UK, is continuing at pace as yet...
Cannabis Telemedicine is Becoming Even More Popular in Germany, Especially in Rural Areas
It is not clear how the new Drugs Commissioner will react to the blistering growth of telemedicine, but it is...
Delaware to Launch Recreational Cannabis Sales on 1 August
Delaware will become the 22nd US state to launch a regulated adult-use cannabis market when retail sales begin on 1...
Key Insights from Mary Jane Berlin x Business of Cannabis’ Inaugural B2B Day
European Cannabis Week 2025 has officially begun, seeing thousands of Europe’s cannabis thought leaders, innovators and decision makers descend on...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags